Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$39.60 -3.0%	$27.87	$16.50 ▼ $40.81	$3.45B	N/A	14,465 shs	6,734 shs
ARWR Arrowhead Pharmaceuticals	$16.08 +0.1%	$15.08	$9.57 ▼ $30.41	$2.22B	0.96	1.53 million shs	2.08 million shs
DNA Ginkgo Bioworks	$9.42 -2.0%	$7.89	$5.00 ▼ $16.85	$551.18M	1.25	1.42 million shs	7.04 million shs
HRMY Harmony Biosciences	$31.98 +0.4%	$32.92	$26.47 ▼ $41.61	$1.84B	0.87	626,390 shs	1.45 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	+5.94%	+62.30%	+80.41%	+3,959,999,900.00%
ARWR Arrowhead Pharmaceuticals	0.00%	+4.96%	+0.12%	+26.22%	-38.13%
DNA Ginkgo Bioworks	0.00%	+10.36%	+35.30%	+65.07%	-29.58%
HRMY Harmony Biosciences	0.00%	+0.28%	-6.98%	-3.65%	+6.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	3.7602 of 5 stars	3.4	2.0	0.0	3.4	2.1	2.5	0.0
DNA Ginkgo Bioworks	0.7913 of 5 stars	0.8	2.0	0.0	0.0	1.8	2.5	1.3
HRMY Harmony Biosciences	4.7685 of 5 stars	4.6	1.0	0.0	0.0	2.8	3.3	4.4

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	171.86% Upside
DNA Ginkgo Bioworks	1.67	Reduce	$5.77	-38.76% Downside
HRMY Harmony Biosciences	3.13	Buy	$53.63	67.68% Upside

Current Analyst Ratings Breakdown

Latest DNA, ARWR, AAPG, and HRMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
4/8/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/8/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	25.68	N/A	N/A	$0.48 per share	82.50
ARWR Arrowhead Pharmaceuticals	$3.55M	625.53	N/A	N/A	$1.54 per share	10.44
DNA Ginkgo Bioworks	$227.04M	2.43	N/A	N/A	$13.17 per share	0.72
HRMY Harmony Biosciences	$714.73M	2.57	$2.95 per share	10.85	$11.56 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.91	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$9.16	N/A	N/A	N/A	-198.84%	-52.35%	-27.14%	8/14/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	12.21	10.28	0.47	20.53%	24.32%	15.92%	8/5/2025 (Estimated)

Latest DNA, ARWR, AAPG, and HRMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
DNA Ginkgo Bioworks	N/A	4.88	4.88
HRMY Harmony Biosciences	0.22	3.67	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ARWR Arrowhead Pharmaceuticals	62.61%
DNA Ginkgo Bioworks	78.63%
HRMY Harmony Biosciences	86.23%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ARWR Arrowhead Pharmaceuticals	4.30%
DNA Ginkgo Bioworks	9.72%
HRMY Harmony Biosciences	23.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable

DNA, ARWR, AAPG, and HRMY Headlines

Recent News About These Companies

First Week of August 15th Options Trading For Harmony Biosciences Holdings (HRMY) - Nasdaq

June 24, 2025 | nasdaq.com

Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY)

June 24, 2025 | msn.com

Analysts Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Target Price at $53.63

June 24, 2025 | americanbankingnews.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Exchange Traded Concepts LLC Takes Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 20, 2025 | marketbeat.com

Harmony Biosciences obtains favorable settlement in litigation over generic Wakix

June 19, 2025 | drugstorenews.comD

SG Americas Securities LLC Has $1.17 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 18, 2025 | marketbeat.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Increase in Short Interest

June 17, 2025 | marketbeat.com

Harmony Biosciences (NASDAQ:HRMY) Trading Down 4.5% - Should You Sell?

June 12, 2025 | marketbeat.com

77,867 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Purchased by CX Institutional

June 12, 2025 | marketbeat.com

Millennium Management LLC Has $218,000 Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on HRMY FY2026 Earnings

June 11, 2025 | marketbeat.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by California State Teachers Retirement System

June 10, 2025 | marketbeat.com

Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory

June 9, 2025 | insidermonkey.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Bridge City Capital LLC

June 9, 2025 | marketbeat.com

Harmony Biosciences Holdings (HRMY) Shares Cross Below 200 DMA

June 7, 2025 | nasdaq.com

Harmony Biosciences settles generic drug litigation, strengthens patent

June 6, 2025 | finance.yahoo.com

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

June 5, 2025 | businesswire.com

Hennion & Walsh Asset Management Inc. Boosts Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 5, 2025 | marketbeat.com

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | businesswire.com

GAMMA Investing LLC Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

June 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA, ARWR, AAPG, and HRMY Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$39.60 -1.21 (-2.96%)

As of 06/27/2025 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.08 +0.01 (+0.06%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$22.11 +6.03 (+37.50%)

As of 04:00 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Ginkgo Bioworks NYSE:DNA

$9.42 -0.19 (-2.01%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$10.34 +0.93 (+9.84%)

As of 05:13 AM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Harmony Biosciences NASDAQ:HRMY

$31.98 +0.12 (+0.38%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$32.15 +0.17 (+0.52%)

As of 04:05 AM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time